Design and synthesis of novel uracil-linked Schiff bases as dual histone deacetylase type II/topoisomerase type I inhibitors with apoptotic potential

Papers of special note have been highlighted as: • of interest

References

• 1. American Cancer Society. Cancer facts and figures 2022 (2023). www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html#:∼:text=Estimatednumbersofnewcancer,incidence%2Cmortality%2Candsurvivalstatistics
  Google Scholar
• 2. Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature 575(7782), 299–309 (2019).
  Medline CASGoogle Scholar
• 3. El-Adl K, Sakr HM, Yousef RG, Mehany ABM, Abulkhair HS, Eissa IH. New quinoxalin-2(1H)-one-derived VEGFR-2 inhibitors: design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies. Arch. Pharm. 355(7), e2200048 (2022).
  Medline CASGoogle Scholar
• 4. Al-Karmalawy AA, Nafie MS, Shaldam MA et al. Ligand-based design on the dog-bone-shaped BIBR1532 pharmacophoric features and synthesis of novel analogues as promising telomerase inhibitors with in vitro and in vivo evaluations. J. Med. Chem. 66(1), 777–792 (2023).
  Medline CASGoogle Scholar
• 5. Skok Ž, Zidar N, Kikelj D, Ilaš J. Dual inhibitors of human DNA topoisomerase II and other cancer-related targets. J. Med. Chem. 63(3), 884–904 (2020). • Describes the benefits of using medications with dual targets to manage chemotherapeutics-resistant cancers.
  Medline CASGoogle Scholar
• 6. Zhou J, Jiang X, He S et al. Rational design of multitarget-directed ligands: strategies and emerging paradigms. J. Med. Chem. 62(20),8881–8914 (2019).
  Medline CASGoogle Scholar
• 7. Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct. Target. Ther. 7(1), 329 (2022).
  Medline CASGoogle Scholar
• 8. Sánchez-Tejeda JF, Sánchez-Ruiz JF, Salazar JR, Loza-Mejía MA. A definition of ‘multitargeticity’: identifying potential multitarget and selective ligands through a vector analysis. Front. Chem. 8, 176 (2020).
  Medline CASGoogle Scholar
• 9. Talevi A. Multi-target pharmacology: possibilities and limitations of the ‘skeleton key approach’ from a medicinal chemist perspective. Front. Pharmacol. 6, 205 (2015)
  MedlineGoogle Scholar
• 10. Vlocskó RB, Apaydın S, Török B, Török M. The multitarget approach as a green tool in medicinal chemistry. In: Contemporary Chemical Approaches for Green and Sustainable Drugs. Elsevier, Amsterdam, The Netherlands, 457–492 (2022).
  Google Scholar
• 11. Bolognesi ML. Polypharmacology in a single drug: multitarget drugs. Curr. Med. Chem. 20(13), 1639–1645 (2013).
  Medline CASGoogle Scholar
• 12. Giordano S, Petrelli A. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem. 15(5), 422–432 (2008).
  MedlineGoogle Scholar
• 13. Shi D, Khan F, Abagyan R. Extended multitarget pharmacology of anticancer drugs. J. Chem. Inf. Model. 59(6), 3006–3017 (2019).
  Medline CASGoogle Scholar
• 14. Gotink KJ, Verheul HMW. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13(1), 1–14 (2010).
  Medline CASGoogle Scholar
• 15. El-Adl K, Ibrahim MK, Khedr F, Abulkhair HS, Eissa IH. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: design, synthesis, molecular docking, and anticancer evaluation studies. Arch. Pharm. 354(3), e202000219 (2021).
  Google Scholar
• 16. El-Adl K, El-Helby AGA, Sakr H et al. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Arch. Pharm. 354(2), e2000279 (2021).
  Medline CASGoogle Scholar
• 17. El-Adl K, Sakr H, El-Hddad SSA, El-Helby AGA, Nasser M, Abulkhair HS. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Arch. Pharm. 354(7), e2000491 (2021).
  Medline CASGoogle Scholar
• 18. El-Shershaby MH, Ghiaty A, Bayoumi AH et al. 1,2,4-Triazolo[4,3-c]quinazolines: a bioisosterism-guided approach towards the development of novel PCAF inhibitors with potential anticancer activity. New J. Chem. 45(25), 11136–11152 (2021).
  CASGoogle Scholar
• 19. Abulkhair HS, Turky A, Ghiaty A, Ahmed HEA, Bayoumi AH. Novel triazolophthalazine-hydrazone hybrids as potential PCAF inhibitors: design, synthesis, in vitro anticancer evaluation, apoptosis, and molecular docking studies. Bioorg. Chem. 100, 103899 (2020).
  Medline CASGoogle Scholar
• 20. Turky A, Bayoumi AH, Ghiaty A, El-Azab AS, A-M Abdel-Aziz A, Abulkhair HS. Design, synthesis, and antitumor activity of novel compounds based on 1,2,4-triazolophthalazine scaffold: apoptosis-inductive and PCAF-inhibitory effects. Bioorg. Chem. 101, 104019 (2020).
  Medline CASGoogle Scholar
• 21. Guerrant W, Patil V, Canzoneri JC, Oyelere AK. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J. Med. Chem. 55(4), 1465–1477 (2012).
  Medline CASGoogle Scholar
• 22. Griffith D, Morgan MP, Marmion CJ. A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. Chem. Commun. (44), 6735–6737 (2009). https://pubs.rsc.org/en/content/articlelanding/2009/cc/b916715c/unauth
  MedlineGoogle Scholar
• 23. Pommier Y, Sun Y, Huang SN, Nitiss JL. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat. Rev. Mol. Cell Biol. 17(11), 703–721 (2016).
  Medline CASGoogle Scholar
• 24. Guo X, Ruan H, Li X et al. Subcellular localization of class I histone deacetylases in the developing Xenopus tectum. Front. Cell. Neurosci. 9, 510 (2016).
  MedlineGoogle Scholar
• 25. He S, Dong G, Wang Z et al. Discovery of novel multiacting topoisomerase I/II and histone deacetylase inhibitors. ACS Med. Chem. Lett. 6(3), 239–243 (2015).
  Medline CASGoogle Scholar
• 26. Guerrant W, Patil V, Canzoneri JC, Yao L-P, Hood R, Oyelere AK. Dual-acting histone deacetylase–topoisomerase I inhibitors. Bioorg. Med. Chem. Lett. 23(11), 3283–3287 (2013).
  Medline CASGoogle Scholar
• 27. Zhang X, Bao B, Yu X et al. The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase. Bioorg. Med. Chem. 21(22), 6981–6995 (2013). • Shows the the utilization of 5-fluorouracil as a key pharmacophore in the structures of structure with reported histone deacetylase (HDAC) and topoisomerase (Topo) inhibitors.
  Medline CASGoogle Scholar
• 28. Cincinelli R, Musso L, Artali R et al. Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents. PLOS ONE 13(10), e0205018 (2018). • Reports the synergistic anticancer effect upon a concurrent treatment with Topo I/HDAC II dual inhibitor medications.
  MedlineGoogle Scholar
• 29. Yeo W-S, Arya R, Kim KK, Jeong H, Cho KH, Bae T. The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus. Sci. Rep. 8(1), 2521 (2018).
  MedlineGoogle Scholar
• 30. Donson AM, Amani V, Warner EA et al. Identification of FDA-approved oncology drugs with selective potency in high-risk childhood ependymoma. Mol. Cancer Ther. 17(9), 1984–1994 (2018).
  Medline CASGoogle Scholar
• 31. Huang J, Huang J, Wang N et al. Identification of 2(1H)-pyrimidinones as potential EGFR T790M inhibitors for the treatment of gefitinib-resistant non-small cell lung cancer. Bioorg. Chem. 89, 102994 (2019).
  Medline CASGoogle Scholar
• 32. Mohamed MFA, Youssif BGM, Shaykoon MSA et al. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors. Bioorg. Chem. 91, 103127 (2019).
  Medline CASGoogle Scholar
• 33. Abd-Elzaher MM, Labib AA, Mousa HA, Moustafa SA, Ali MM, El-Rashedy AA. Synthesis, anticancer activity and molecular docking study of Schiff base complexes containing thiazole moiety. Beni-Suef Univ. J. Basic Appl. Sci. 5(1), 85–96 (2016).
  Google Scholar
• 34. Hassanin HM, Serya RAT, Abd Elmoneam WR, Mostafa MA. Synthesis and molecular docking studies of some novel Schiff bases incorporating 6-butylquinolinedione moiety as potential topoisomerase IIβ inhibitors. R. Soc. Open Sci. 5(6), 172407 (2018).
  MedlineGoogle Scholar
• 35. El-Malah A, Taher ES, Angeli A et al. Schiff bases as linker in the development of quinoline-sulfonamide hybrids as selective cancer-associated carbonic anhydrase isoforms IX/XII inhibitors: a new regioisomerism tactic. Bioorg. Chem. 131, 106309 (2023).
  Medline CASGoogle Scholar
• 36. Yu C-C, Pan S-L, Chao S-W et al. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I. Biochem. Pharmacol. 90(3), 320–330 (2014). • Reports the synergistic anticancer effect upon a concurrent treatment with Topo I/HDAC II dual inhibitor medications.
  Medline CASGoogle Scholar
• 37. Proschak E, Stark H, Merk D. Polypharmacology by design: a medicinal chemist’s perspective on multitargeting compounds. J. Med. Chem. 62(2), 420–444 (2019).
  Medline CASGoogle Scholar
• 38. Liu Y-Q, Dai W, Yang L, Li H-Y. Design and synthesis of novel camptothecin/5-fluorouracil conjugates as cytotoxic agents. Nat. Prod. Res. 25(19), 1817–1826 (2011).
  Medline CASGoogle Scholar
• 39. Ma Z, Gao G, Fang K, Sun H. Development of novel anticancer agents with a scaffold of tetrahydropyrido [4, 3-d] pyrimidine-2, 4-dione. ACS Med. Chem. Lett. 10(2), 191–195 (2019).
  Medline CASGoogle Scholar
• 40. Lu G, Li X, Wang D, Meng F. Design, synthesis and biological evaluation of novel uracil derivatives bearing 1,2,3-triazole moiety as thymidylate synthase (TS) inhibitors and as potential antitumor drugs. Eur. J. Med. Chem. 171, 282–296 (2019).
  Medline CASGoogle Scholar
• 41. Ezzat HG, Bayoumi AH, Sherbiny FF et al. Design, synthesis, and molecular docking studies of new [1,2,4]triazolo[4,3-a]quinoxaline derivatives as potential A2B receptor antagonists. Mol. Divers. 25(1), 291–306 (2021).
  Medline CASGoogle Scholar
• 42. Abul-Khair H, Elmeligie S, Bayoumi A, Ghiaty A, El-Morsy A, Hassan MH. Synthesis and evaluation of some new (1,2,4) triazolo(4,3-a)quinoxalin-4(5h)-one derivatives as AMPA receptor antagonists. J. Heterocycl. Chem. 50(5), 1202–1208 (2013).
  CASGoogle Scholar
• 43. Abulkhair HS, Elmeligie S, Ghiaty A et al. In vivo- and in silico-driven identification of novel synthetic quinoxalines as anticonvulsants and AMPA inhibitors. Arch. Pharm. 354(5), e2000449 (2021).
  Medline CASGoogle Scholar
• 44. Aljuhani A, Ahmed HEA, Ihmaid SK et al. In vitro and computational investigations of novel synthetic carboxamide-linked pyridopyrrolopyrimidines with potent activity as SARS-CoV-2-M Pro inhibitors. RSC Adv. 12(41), 26895–26907 (2022).
  Medline CASGoogle Scholar
• 45. Othman EM, Fayed EA, Husseiny EM, Abulkhair HS. Rationale design, synthesis, cytotoxicity evaluation, and in silico mechanistic studies of novel 1,2,3-triazoles with potential anticancer activity. New J. Chem. 46, 12206–12216 (2022).
  CASGoogle Scholar
• 46. Othman EM, Fayed EA, Husseiny EM, Abulkhair HS. The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia. Bioorg. Chem. 127, 105968 (2022).
  Medline CASGoogle Scholar
• 47. Husseiny EM, Abulkhair HS, El-Dydamony NM, Anwer KE. Exploring the cytotoxic effect and CDK-9 inhibition potential of novel sulfaguanidine-based azopyrazolidine-3,5-diones and 3,5-diaminoazopyrazoles. Bioorg. Chem. 133, 106397 (2023).
  Medline CASGoogle Scholar
• 48. Lv Z, Weng X, Du C et al. Downregulation of HDAC6 promotes angiogenesis in hepatocellular carcinoma cells and predicts poor prognosis in liver transplantation patients. Mol. Carcinog. 55(5), 1024–1033 (2016).
  Medline CASGoogle Scholar
• 49. Gray J, Cubitt CL, Zhang S, Chiappori A. Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biol. Ther. 13(8), 614–622 (2012).
  Medline CASGoogle Scholar
• 50. Li W, Wu H, Sui S, Wang Q, Xu S, Pang D. Targeting histone modifications in breast cancer: a precise weapon on the way. Front. Cell Dev. Biol. 9, 736935 (2021).
  MedlineGoogle Scholar
• 51. El-Sabbagh OI, El-Sadek ME, El-Kalyoubi S, Ismail I. Synthesis, DNA binding and antiviral activity of new uracil, xanthine, and pteridine derivatives. Arch. Pharm. 340(1), 26–31 (2007). • Reports the synthetic procedure of 5,6-diamino-1,3-dimethyluracil hydrochloride (17a).
  Medline CASGoogle Scholar
• 52. Mousa BA, Bayoumi AH, Korraaa MM, Assy MG, El-Kalyoubi SA. One pot synthesis, DNA binding and fragmentation in vitro of new fused uracil derivatives for anticancer properties. Afinidad 69(559), 224–228 (2012). • Reports the synthetic procedure of 5,6-diamino-1,3-dimethyluracil hydrochloride (17a).
  CASGoogle Scholar
• 53. El-Kalyoubi S, Agili F, Adel I, Tantawy MA. Novel uracil derivatives depicted potential anticancer agents: in vitro, molecular docking, and ADME study. Arab. J. Chem. 15(4), 103669 (2022).
  CASGoogle Scholar
• 54. Farag B, Agili F, El-Kalyoubi S, Said SA, Youssif S, Shehta W. Synthesis, molecular docking and anticancer activity of some 5-aryl-5, 10-dihydropyrido [2, 3-d: 6, 5-d′] dipyrimidine-2, 4, 6, 8-tetraone derivatives and pyrido [2, 3-d] pyrimidines. ChemistrySelect 7(7), e202103834 (2022).
  CASGoogle Scholar
• 55. El-Kalyoubi S, Agili F, Zordok WA, El-Sayed ASA. Synthesis, in silico prediction and in vitro evaluation of antimicrobial activity, dft calculation and theoretical investigation of novel xanthines and uracil containing imidazolone derivatives. Int. J. Mol. Sci. 22(20), 10979 (2021).
  Medline CASGoogle Scholar
• 56. El-Kalyoubi S, Agili F. Synthesis, in silico prediction and in vitro evaluation of antitumor activities of novel pyrido [2,3-d] pyrimidine, xanthine and lumazine derivatives. Molecules 25(21), 5205 (2020).
  Medline CASGoogle Scholar
• 57. El-Kalyoubi SA, Ragab A, Abu Ali OA et al. One-pot synthesis and molecular modeling studies of new bioactive spiro-oxindoles based on uracil derivatives as SARS-CoV-2 inhibitors targeting RNA polymerase and spike glycoprotein. Pharmaceuticals 15(3), 376 (2022).
  Medline CASGoogle Scholar
• 58. El-Kalyoubi SA, Taher ES, Ibrahim TS, El-Behairy MF, Al-Mahmoudy AMM. Uracil as a Zn-binding bioisostere of the allergic benzenesulfonamide in the design of quinoline–uracil hybrids as anticancer carbonic anhydrase inhibitors. Pharmaceuticals 15(5), 494 (2022).
  Medline CASGoogle Scholar
• 59. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 3(7), 207–212 (1991).
  Medline CASGoogle Scholar
• 60. Bradner JE, West N, Grachan ML et al. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6(3), 238–243 (2010).
  Medline CASGoogle Scholar
• 61. Urda C, Fernández R, Rodríguez J, Pérez M, Jiménez C, Cuevas C. Bistratamides M and N, oxazole-thiazole containing cyclic hexapeptides isolated from Lissoclinum bistratum interaction of zinc(II) with bistratamide K. Mar. Drugs 15(7), 209 (2017).
  MedlineGoogle Scholar
• 62. Vermes I, Haanen C, Steffens-Nakken H, Reutellingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods 184(1), 39–51 (1995).
  Medline CASGoogle Scholar
• 63. Kim KH, Sederstrom JM. Assaying cell cycle status using flow cytometry. Curr. Protoc. Mol. Biol. 111(1), 28.6.1–28.6.11 (2015).
  MedlineGoogle Scholar
• 64. Chemical Computing Group, Inc. Molecular Operating Environment (MOE 2019.0102). https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=+Molecular+Operating+Environment+%28MOE+2019.0102%29&btnG=
  Google Scholar
• 65. Abo Elmaaty A, Eldehna W, Khattab M et al. Anticoagulants as potential SARS-CoV-2 Mpro inhibitors for COVID-19 patients: in vitro, molecular docking, molecular dynamics, DFT, and SAR studies. Int. J. Mol. Sci. 23(20), 12235 (2022).
  MedlineGoogle Scholar
• 66. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7(1), 42717 (2017).
  MedlineGoogle Scholar
• 67. Khedr F, Ibrahim MK, Eissa IH, Abulkhair HS, El-Adl K. Phthalazine-based VEGFR-2 inhibitors: rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations. Arch. Pharm. 354(11), e2100201 (2021).
  Medline CASGoogle Scholar
• 68. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65(1–2), 55–63 (1983).
  Medline CASGoogle Scholar
• 69. Maioral MF, Bodack CDN, Stefanes NM et al. Cytotoxic effect of a novel naphthylchalcone against multiple cancer cells focusing on hematologic malignancies. Biochimie 140, 48–57 (2017).
  Medline CASGoogle Scholar
• 70. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70(1), 369–413 (2001).
  Medline CASGoogle Scholar
• 71. Baker NM, Rajan R, Mondragon A. Structural studies of type I topoisomerases. Nucleic Acids Res. 37(3), 693–701 (2009).
  Medline CASGoogle Scholar
• 72. Elmore S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35(4), 495–516 (2007).
  Medline CASGoogle Scholar
• 73. Othman EM, Fayed EA, Husseiny EM, Abulkhair HS. Apoptosis induction, PARP-1 inhibition, and cell cycle analysis of leukemia cancer cells treated with novel synthetic 1,2,3-triazole-chalcone conjugates. Bioorg. Chem. 123, 105762 (2022).
  Medline CASGoogle Scholar
• 74. Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res. Int. 2014, 1–23 (2014).
  Google Scholar
• 75. Wang Y, Ji P, Liu J, Broaddus RR, Xue F, Zhang W. Centrosome-associated regulators of the G2/M checkpoint as targets for cancer therapy. Mol. Cancer 8(1), 8 (2009).
  MedlineGoogle Scholar
• 76. Shabnam MS, Srinivasan R, Wali A, Majumdar S, Joshi K, Behera D. Expression of p53 protein and the apoptotic regulatory molecules Bcl-2, Bcl-XL, and Bax in locally advanced squamous cell carcinoma of the lung. Lung Cancer 45(2), 181–188 (2004).
  MedlineGoogle Scholar
• 77. Mirjolet J-F, Barberi-Heyob M, Didelot C et al. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br. J. Cancer 83(10), 1380–1386 (2000).
  Medline CASGoogle Scholar
• 78. Hammoud MM, Khattab M, Abdel-Motaal M et al. Synthesis, structural characterization, DFT calculations, molecular docking, and molecular dynamics simulations of a novel ferrocene derivative to unravel its potential antitumor activity. J. Biomol. Struct. Dyn. 1–18. doi: 10.1080/07391102.2022.2082533 (2022) (Epub ahead of print).
  Google Scholar
• 79. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl Acad. Sci. USA 99(24), 15387–15392 (2002).
  Medline CASGoogle Scholar
• 80. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23(1–3), 3–25 (1997).
  CASGoogle Scholar
• 81. Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45(12), 2615–2623 (2002).
  Medline CASGoogle Scholar
• 82. Wang R, Fu Y, Lai L. A new atom-additive method for calculating partition coefficients. J. Chem. Inf. Comput. Sci. 37(3), 615–621 (1997).
  CASGoogle Scholar
• 83. Daina A, Zoete V. A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 11(11), 1117–1121 (2016).
  Medline CASGoogle Scholar
• 84. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar